ロード中...

Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF

BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anti-cancer drug development. Wild-type BRAF and a variety of oncogenic BRAF mutants are dependent on dimerization of the kinase domain, w...

詳細記述

保存先:
書誌詳細
出版年:ACS Chem Biol
主要な著者: Gunderwala, Amber Y., Nimbvikar, Anushri A., Cope, Nicholas J., Li, Zhijun, Wang, Zhihong
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733264/
https://ncbi.nlm.nih.gov/pubmed/31243962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00191
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!